lynparza
NICE demands more evidence of Lynparza benefits
August 6, 2015Sales and Marketing AstraZeneca, NICE, lynparza, ovarian cancer
AstraZeneca must provide a “robust estimate of the cost effectiveness” of its ovarian cancer treatment Lynparza, or risk being rejected …
NICE Lynparza rejection labelled ‘hard to understand’
June 2, 2015Sales and Marketing AstraZeneca, NICE, lynparza, olaparib
AstraZeneca has appealed to the government to put ‘urgent transitional measures’ in place to make sure patients can access innovative …
AstraZeneca drops CDF application
January 12, 2015Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib
AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …
AstraZeneca ovarian cancer drug approved in Europe
December 18, 2014Sales and Marketing AstraZeneca, BRCA, Cambridge, Cancer, FDA, lynparza, olaparib, ovarian
The European Commission has approved AstraZeneca’s Lynparza for the treatment of advanced BRCA-mutated ovarian cancer. Lynparza (olaparib) has been approved …
AZ oncology drug a ‘Phoenix from the flames’
October 27, 2014Sales and Marketing AstraZeneca, CHMP, EC, lynparza, olaparib, oncology
As the possibility of a deal with Pfizer fades, AstraZeneca is continuing its argument for independence as a key cancer …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
